CHRS Aug 2023 7.500 call
| Previous close | 0.6000 |
| Open | 0.5500 |
| Bid | 0.3000 |
| Ask | 0.6000 |
| Strike | 7.50 |
| Expiry date | 2023-08-18 |
| Day's range | 0.5300 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 604 |
ZacksCoherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Investing.com
6 analyst picks: Lululemon sparkles | Pro Recap
Citi upgraded Lululemon Athletica (NASDAQ:LULU) to Buy from Neutral this morning with a price target of $440.00, up from $350.00, after yesterday's better-than-expected earnings report.
- Zacks
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksCoherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksHere's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing
Coherus BioSciences (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
ZacksWall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Coherus BioSciences (CHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Motley FoolCoherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript
This release can be found on the Coherus BioSciences website and is also attached to our Form 8-K. Today's call includes forward-looking statements regarding Coherus' current expectations about future events. All these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from results, performance or achievements implied by the forward-looking statements.
ZacksCoherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksWall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know
The consensus price target hints at an 84.6% upside potential for Coherus BioSciences (CHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksSwedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.